登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，5月24日，Anti-SARS-CoV-2 IgG antibodies are associated with reduced viral load》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-05-25

  • Anti-SARS-CoV-2 IgG antibodies are associated with reduced viral load

    Andrew Bryan, Susan L Fink, Meghan A Gattuso, Gregory Pepper, Anu Chaudhary, Mark Wener, Chihiro Morishima, Keith Jerome, View ORCID ProfilePatrick C Mathias, View ORCID ProfileAlexander L Greninger

    doi: https://doi.org/10.1101/2020.05.22.20110551

    Abstract

    Anti-SARS-CoV-2 antibodies have been described, but correlation with virologic outcomes is limited. Here, we find anti-SARS-CoV-2 IgG to be associated with reduced viral load. High viral loads were rare in individuals who had seroconverted. Higher viral load on admission was associated with increased 30-day mortality (OR 4.20 [95% CI: 1.62-10.86]).

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.05.22.20110551v1
24浏览量
原文链接
相关报告

  • 《5月24日_SARS-CoV-2 IgG抗体与病毒载量降低有关》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-25
    • 信息名称：SARS-CoV-2 IgG抗体与病毒载量降低有关 1.时间：2020年5月24日 2.机构或团队：华盛顿大学医学院、Aquaelis公司、华盛顿大学 3.事件概要： 华盛顿大学医学院等于5月24日在medRxiv上发表题为“Anti-SARS-CoV-2 IgG antibodies are associated with reduced viral load”的文章。文章指出，已有研究描述了SARS-CoV-2抗体，但针对其与病毒学结果相关性的研究有限。文章中，研究人员发现SARS-CoV-2 IgG抗体与病毒载量降低有关。高病毒载量在血清转化个体中很少见。入院时较高的病毒载量与30天死亡率增加有关（OR 4.20[95% CI：1.62-10.86]）。 *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用。 4.附件： 原文链接： https://www.medrxiv.org/content/10.1101/2020.05.22.20110551v1
    19浏览量
    原文链接

  • 《Lancet，6月11日，Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-12
    • Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Silvia Stringhini, PhD Ania Wisniak, MS † Giovanni Piumatti, PhD † Andrew S Azman, PhD † Stephen A Lauer, PhD Hélène Baysson, PhD et al. Published:June 11, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31304-0 Summary Background Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic. Methods The SEROCoV-POP study is a population-based study of former participants of the Bus Santé study and their household members. We planned a series of 12 consecutive weekly serosurveys among randomly selected participants from a previous population-representative survey, and their household members aged 5 years and older. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. We estimated seroprevalence using a Bayesian logistic regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Here we present results from the first 5 weeks of the study.
    17浏览量
    原文链接